Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and ...
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on …